PD-1 agonist: A novel therapeutic approach to resolve atherosclerosis by Jiahui Chen, Wanqian Yu, Le Liao, Linghua Fu, Pingping Yang

Subjects: “…PD-1 agonists…”
Get full text

Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation by Itamar Averbuch, Nofar Edri, Nethanel Asher, Gal Markel, Daniel Hendler, Hadas Ditzian Kugler, Eyal Yosefof, Noga Kurman

Subjects: Get full text

Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review by D. D. Ivanova, E. A. Baryakh, M. A. Mingalimov, E. N. Misyurina, D. S. Polyakov, N. A. Savosina, M. M. Beregov, M. A. Donskoy, A. B. Makeshova, T. N. Tolstykh, O. L. Kochneva, T. S. Kravchuk, E. I. Zhelnova, K. V. Yatskov, A. Kh. Mnoyan, I. M. Grashchenko, N. A. Shevchenko, A. A. Vinokurov, I. V. Samsonova, M. A. Lysenko

Subjects: Get full text

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma by Jacek Mackiewicz, Andrzej Mackiewicz

Subjects: Get full text

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-worl... by Baoyue Pan, He Huang, Ting Wan, Qidan Huang, Shanyang He, Shijie Xu, Siyu Chen, Jiaxin Yin, Jundong Li, Min Zheng

Subjects: Get full text

Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition by Laura Codarri Deak, Masao Hashimoto, Pablo Umaña, Christian Klein

Subjects: Get full text

PD1+ Treg cell remodeling promotes immune homeostasis within peripheral blood and tumor microenvironment after microparticles-transarterial chemoembolization in hepatocellular carc... by Zhizhong Ren, Yaqin Wang, Dandan Jiang, Ying Liu, Xiaowei Yang, Tianxiao Wang, Junqi Zhu, Wenya Wang, Qian Chen, Yuewei Zhang

Subjects: Get full text

Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma by Jennifer A. Lenz, Brandon Peng, Charles‑Antoine Assenmacher, Austin King, Paul J. Zhang, Robert G. Maki, M. Andres Blanco, Enrico Radaelli, Matthew J. Atherton

Subjects: Get full text

Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade by Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima

Subjects: “…pd-1…”
Get full text

Activated platelets stimulate effector CD8+ T cells to enhance HNSCC immunotherapy efficacy by Zhennan Yuan, Lunhua Guo, Yuheng Pang, Wenjing Wang, Yuefeng Shang, Chufei Xie, Cheng Qian, Ji Sun, Xiaohong Wu

Subjects: Get full text

Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model by Felipe F. Lamenza, Peyton Roth, Puja Upadhaya, Suvekshya Shrestha, Sushmitha Jagadeesha, Natalie Kazmierowicz, Natalie Horn, Hasan Pracha, Sonali Dasari, Steve Oghumu

Subjects: Get full text

Promising New Anti‐TIGIT Agents: Stealthy Allies in Cancer Immunotherapy by Gatadi Srikanth, Durga Prasad Beda, Ashish Ranjan Dwivedi, Nandan Kumar Duddukuri, Srinivas Nanduri, Jitendra Patel

Subjects: Get full text

Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study by Dmitry Shchelokov, Oleg Demin Jr

Subjects: Get full text

Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma by Luigi Liguori, Angelo Luciano, Valentina Pagliara, Giovanna Polcaro, Rosario De Feo, Angela Viggiano, Fabio Salomone, Annarita Avanzo, Filippo Vitale, Simeone D’ambrosio, Alberto Servetto, Cristina R. Ferrone, Stefano Pepe, Francesco Sabbatino

Subjects: Get full text

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1 by Mengzhen Jiang, Man Liu, Guodi Liu, Jiawen Ma, Lixin Zhang, Shenlin Wang

Subjects: Get full text

Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma by Yaru Gao, Yue Huo, Lingli Wang, Jiayi Ruan, Lanzhen Chen, Hongdong Li, Guini Hong

Subjects: Get full text

Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma by JIANG Jiayun, ZHANG Hui, ZHANG Shiyu

Subjects: Get full text

Tyrosinase in melanoma inhibits anti-tumor activity of PD-1 deficient T cells by Rong Huang, Yingbin Wang, Haitao Teng, Mengjun Xu, Kexin He, Yingzhuo Shen, Guo Guo, Xinyu Feng, Tianhan Li, Binhui Zhou, Marc Bajenoff, Toby Lawrence, Yinming Liang, Liaoxun Lu, Lichen Zhang

Subjects: Get full text

AHR Agonist ITE Boosted PD1 Antibody’s Effects by Inhibiting Myeloid-Derived Cells Suppressive Cells in an Orthotopic Mouse Glioma Model by Pei Gong, Lijiao Zhao, Yunlong Ma, Qiuting Shu, Hui Sun, Jing Lu, Fanhua Meng, Fang Wan

Subjects: Get full text

Genomic and clinical characterization of pediatric lymphoepithelioma-like carcinoma by Yi Que, Xiuxia Lu, Suying Lu, Feifei Sun, Jia Zhu, Yu Zhang, Juan Wang, Junting Huang, Wei Liu, Fenghua Wang, Liping Li, Li Zhang, Min Gao, Zijun Zhen, Yizhuo Zhang

Subjects: Get full text